Table 1.
Baseline characteristics.
| Baseline characteristic | Total cohort (n = 343) |
|---|---|
| Age, y (mean, SD) | 60.52 ± 8.48 |
| Gender | |
| Male | 208 |
| Female | 135 |
| Race | |
| African American | 191 (55.69%) |
| Caucasian | 124 (36.15%) |
| Hispanic | 24 (7%) |
| Others | 4 (1.16%) |
| Treatment naïve | 291 (84.84%) |
| NAFLD | 161 (46.94%) |
| BAFLD | 74 (21.57%) |
| Genotype | |
| IA | 225 (65.60%) |
| IB | 56 (16.33%) |
| Other | 62 (18.07) |
| Treatment | |
| Harvoni® | 162 (47.23%) |
| Harvoni® +Ribavirin | 22 (6.41%) |
| Zepatier® | 70 (20.41%) |
| Epclusa® | 50 (15%) |
| Other | 34 (16.04%) |
| IR/DM | 142 (41.40%) |
| Hb A1c | 6.17 ± 1.83 gm/dL |
| Alcohol use disorder | 146 (42.57%) |